Anxiolytic- and antidepressant-like effects of 7-OH-DPAT, preferential dopamine D3 receptor agonist, in rats

Polish Journal of Pharmacology

Volumn 56, Issue 5, 2004, Pages 519-526

  Rogóz, Zofia ^a   Skuza, Grazyna ^a   Kłodzinska, Aleksandra ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

7 OH DPAT; BP 897; Elevated plus maze test; Forced swimming test; Rat

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; BP 897; DIAZEPAM; DOPAMINE 3 RECEPTOR STIMULATING AGENT; IMIPRAMINE;

ANIMAL EXPERIMENT; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG MEGADOSE; DRUG POTENCY; FORCED SWIMMING TEST; IMMOBILIZATION; LOCOMOTION; LOW DRUG DOSE; MALE; MAZE TEST; MOTOR COORDINATION; NONHUMAN; RAT; RAT STRAIN; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; DOPAMINE AGONISTS; MALE; MAZE LEARNING; MOTOR ACTIVITY; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; TETRAHYDRONAPHTHALENES;

EID: 12344275295     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Bartoszyk GD: Anxiolytics effects of dopamine receptor ligands: I. Involvement of dopamine autoreceptors. Life Sci, 1998, 62, 649-663.
2. Becker PM, Corrigan MH, Kasper S, Lin S-C, Montplaisir J, Szegedi A, Willner P: Clinical efficacy of pramipexole in the treatment of conditions other than Parkinson's disease. Rev Contemp Pharmacother, 2001, 12, 87-104.
3. 2 receptor mRNA. Brain Res, 1991, 564, 203-219.
4. Cabib S, Puglissi-Allerga S: Opposite responses of mesolimbic dopamine system to controllable and uncontrollable aversive experiences. J Neurosci, 1994, 14, 3333-3340.
5. 3 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur J Pharmacol, 1991, 200, 65-72.
6. Costall B, Hendrie CA, Kelly ME, Naylor RJ: Actions of sulpiride and tiapride in a simple model of anxiety in mice. Neuropharmacology, 1987, 26, 195-200.
7. 3 receptor ligand. Eur J Pharmacol, 1993, 249, R9-R10.
8. D'Aquila PS, Collu M, Gessa GL, Serra G: The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol, 2000, 405, 365-373.
9. Dunn AJ: Stress-related activation of cerebral dopaminergic systems. Ann NY Acad Sci, 1988, 537, 188-205.
10. Ferrari F, Giuliani D: Effect of (-)eticlopride and 7-OH-DPAT on the tail-suspension test in mice. J Psychopharmacol, 1997, 11, 339-344.
11. Finlay JM, Zigmond MJ, Abercrombie ED: Increased dopamine and norepinephrine release in medial prefrontal cortex induced by acute and chronic stress: effects of diazepam. Neuroscience, 1995, 64, 619-628.
12. 3 receptor in the presynaptic regulation of dopamine release but not synthesis. Eur J Pharmacol, 1996, 308, 261-269.
13. Gao B, Cutler MG: Effects of quinpirole on the behaviour shown by mice in the light-dark box and during social interactions. Neuropharmacology, 1993, 32, 93-100.
14. 3 receptor antagonist PNU 99194A on motor behavior and emotional reactivity in C 57 BL/6J mice. Eur J Pharmacol, 1997, 337, 147-155.
15. 3 receptors. Eur J Pharmacol, 1995, 272, R1-R3.
16. Imperato A, Puglisi-Allegra S, Zocchi A, Scrocco MG, Casolini P, Angelucci L: Stress activation of limbic and cortical dopamine release is prevented by ICS 205-930 but not diazepam. Eur J Pharmacol, 1990, 182, 211-214.
17. Kłodzińska A, Tatarczyńska E, Stachowicz K, Chojnacka-Wójcik E: The anxiolytic-like action of AIDA (1-aminoindan-1,5-dicarboxylic acid), an mGLu 1 receptor antagonist. J Physiol Pharmacol, 2004, 55, 113-126.
18. 3 receptor binding affinity. Eur J Pharmacol, 1995, 277, 209-214.
19. 3 receptor gene expression as a commen effect of chronic antidepressant treatments. Mol Psychiat, 2000, 5, 378-388.
20. 3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA, 1992, 89, 8155-8159.
21. 3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc Nat Acad Sci USA, 1995, 92, 1719-1723.
22. Maj J: Antidepressant given repeatedly: pharmacological evaluation of their action. Pol J Pharmacol, 1991, 43, 241-254.
23. 3 receptors in the rat brain. Eur J Pharmacol, 1998, 351, 31-37.
24. Maj J, Rogóz Z: Synergistic effects of pramipexole and sertraline in the forced swimming test. Pol J Pharmacol, 1999, 51, 471-475.
25. Maj J, Rogóz Z, Skuza G, Kołodziejczyk K: Antidepressant effect of pramipexole, a novel dopamine receptor agonist. J Neural Transm, 1997, 104, 525-533.
26. 2 receptor agonist. Eur J Pharmacol, 1992, 215, 161-170.
27. 4 receptors. Mol Pharmacol, 1995, 290, 29-36.
28. 3 receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther, 2000, 293, 1048-1062.
29. Pellow S, File SE: Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav, 1986, 24, 525-529.
30. Pich EM, Samanin R: Disinhibitory effects of buspirone and low doses of sulpiride and haloperidol in two experimental anxiety models in rats: possible role of dopamine. Psychopharmacology, 1986, 89, 125-130.
31. 3 receptor agonist. Nature, 1999, 400, 371-375.
32. Porsolt RD, Anton G, Blavet N, Jalfre M: Behavioral despair in rats, a new model sensitive to antidepressant treatment. Eur J Pharmacol, 1978, 47, 379-391.
33. 3-receptor agonist 7-OH-DPAT. Pharmacol Biochem Behav, 1996, 54, 79-84.
34. 3 receptor ligands modulate the behaviour of mice in the elevated plus-maze. Pharmacol Biochem Behav, 1994, 49, 985-995.
35. 3 antagonist U-99194A maleate increases social behaviors of isolation-induced aggressive male mice. Psychopharmacology, 1999, 144, 90-94.
36. 3 receptor antagonists, in animal models. Pol J Pharmacol, 2000, 52, 459-462.
37. 3 receptors. Pol J Pharmacol, 2001, 53, 571-576.
38. 3 receptor agonists in an animal model. Pol J Pharmacol, 2003, 55, 455-460.
39. Salamone JD: The involvement of nucleus accumbens dopamine in appetitive and aversive motivation. Behav Brain Res, 1994, 61, 117-133.
40. Simon P, Panissaud C, Costentin J: Anxiogenic-like effects induced by stimulation of dopamine receptors. Pharmacol Biochem Behav, 1993, 45, 685-690.
41. 3 receptors. Psychopharmacology, 2004, 175, 163-169.
42. 3 as a target for neuroleptics. Nature, 1990, 347, 146-151.
43. 3 dopamine receptor-deficient mouse: evidence for reduced anxiety. Physiol Behav, 1998, 63, 137-141.
44. Takamari K, Yoshida S, Okuyama S: Repeated treatment with imipramine, fluoxamine and tranylcypramine decreases the number of escape failures by activating dopaminergic systems in a rat learned helplessness test. Life Sci, 2001, 69, 1919-1926.
45. Vetulani J, Nalepa I: Antidepressants; past, present and future. Eur J Pharmacol, 2000, 405, 351-363.
46. Willner P: The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol, 1997, 12, Suppl 3, S7-S14.
47. Willner P, Lappas S, Cheeta S, Muscat R: Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology, 1994, 115, 454-462.